These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36841245)

  • 1. Factor XI Inhibitors in Early Clinical Trials: A Meta-analysis.
    Galli M; Laborante R; Ortega-Paz L; Franchi F; Rollini F; D'Amario D; Capodanno D; Tremoli E; Gibson CM; Mehran R; Angiolillo DJ
    Thromb Haemost; 2023 Jun; 123(6):576-584. PubMed ID: 36841245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor XI as a new target for prevention of thromboembolism in cardiovascular disease: a meta-analysis of randomized controlled trials.
    Ali AE; Awad MK; Ali K; Abouzid MR; Ahmed MH; Mazroua MS
    J Thromb Thrombolysis; 2024 May; ():. PubMed ID: 38762711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
    Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trials.
    Galli M; Capodanno D; Benenati S; D'Amario D; Crea F; Andreotti F; Angiolillo DJ
    Eur Heart J Cardiovasc Pharmacother; 2022 Aug; 8(5):519-528. PubMed ID: 34146091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor XI antisense oligonucleotide for prevention of venous thrombosis.
    Büller HR; Bethune C; Bhanot S; Gailani D; Monia BP; Raskob GE; Segers A; Verhamme P; Weitz JI;
    N Engl J Med; 2015 Jan; 372(3):232-40. PubMed ID: 25482425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. News at XI: moving beyond factor Xa inhibitors.
    Fredenburgh JC; Weitz JI
    J Thromb Haemost; 2023 Jul; 21(7):1692-1702. PubMed ID: 37116752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effectiveness and safety of direct oral anticoagulants compared to conventional pharmacologic thromboprophylaxis in hip fracture patients: A systematic review and meta-analysis of randomized controlled trials.
    Abatzis-Papadopoulos M; Tigkiropoulos K; Nikas S; Papoutsis I; Kostopoulou O; Stavridis K; Karamanos D; Lazaridis I; Saratzis N
    Orthop Traumatol Surg Res; 2023 Apr; 109(2):103364. PubMed ID: 35817368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis.
    Albertsen IE; Larsen TB; Rasmussen LH; Overvad TF; Lip GY
    Drugs; 2012 Sep; 72(13):1755-64. PubMed ID: 22876779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
    Nieto JA; Espada NG; Merino RG; González TC
    Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents.
    Kahale LA; Matar CF; Tsolakian I; Hakoum MB; Yosuico VE; Terrenato I; Sperati F; Barba M; Hicks LK; Schünemann H; Akl EA
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD014739. PubMed ID: 34582035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: A systematic review and meta-analysis.
    Alhousani M; Malik SU; Abu-Hashyeh A; Poznanski NJ; Al-Hasan S; Roth DF; Alsharedi M; Mustafa B
    Thromb Res; 2021 Feb; 198():103-114. PubMed ID: 33310644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual therapy with oral anticoagulation and single antiplatelet agent versus monotherapy with oral anticoagulation alone in patients with atrial fibrillation and stable ischemic heart disease: a systematic review and meta-analysis.
    Shakir A; Khan A; Agarwal S; Clifton S; Reese J; Munir MB; Nasir UB; Khan SU; Gopinathannair R; DeSimone CV; Deshmukh A; Jackman WM; Stavrakis S; Asad ZUA
    J Interv Card Electrophysiol; 2023 Mar; 66(2):493-506. PubMed ID: 36085242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk.
    Zhang H; Löwenberg EC; Crosby JR; MacLeod AR; Zhao C; Gao D; Black C; Revenko AS; Meijers JC; Stroes ES; Levi M; Monia BP
    Blood; 2010 Nov; 116(22):4684-92. PubMed ID: 20807891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor XI, a potential target for anticoagulation therapy for venous thromboembolism.
    Li T; Liu J; Wu W
    Front Cardiovasc Med; 2022; 9():975767. PubMed ID: 36386334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
    Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review of randomized controlled trials of new anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries, compared with enoxaparin.
    Yoshida Rde A; Yoshida WB; Maffei FH; El Dib R; Nunes R; Rollo HA
    Ann Vasc Surg; 2013 Apr; 27(3):355-69. PubMed ID: 23351997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor XI inhibition in patients with acute coronary syndrome.
    Raffo C; Capodanno D
    Eur Heart J Suppl; 2024 Apr; 26(Suppl 1):i29-i34. PubMed ID: 38867863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: Updated systematic review and meta-analysis of randomized controlled trials.
    Moik F; Posch F; Zielinski C; Pabinger I; Ay C
    Res Pract Thromb Haemost; 2020 May; 4(4):550-561. PubMed ID: 32548553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials.
    Cao YB; Zhang JD; Shen H; Jiang YY
    Eur J Clin Pharmacol; 2010 Nov; 66(11):1099-108. PubMed ID: 20812009
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.